Craig Portell

2 days ago | ajmc.com | Maggie L. Shaw |Craig Portell

In February, the FDA approved a novel triplet combination for relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma, based on data from the ongoing phase 3 ECHELON-3 trial (NCT04404283), in which patients have been randomized 1:1 to receive brentuximab vedotin (Adcetris; Seagen)/lenalidomide/rituximab or placebo/lenalidomide/rituximab. Principal investigator Craig A.